Alpha-Lipoic Acid and Benfotiamine in Diabetic Peripheral Neuropathy: A Critical Review of Mechanistic Rationale and Clinical Evidence Within a Nutritional Therapeutic Framework.
Level 5 - mechanism / opinion, no new human data
Structured narrative review and mechanism-based qualitative synthesis
PubMed 42196997 · doi:10.3390/nu18101538
What was done
A structured narrative review of PubMed/MEDLINE was conducted to critically evaluate the mechanistic rationale and clinical evidence for alpha-lipoic acid (ALA) and benfotiamine as adjunctive metabolic treatments for diabetic peripheral neuropathy (DPN). The authors qualitatively synthesized findings from randomized controlled trials, clinical studies, systematic reviews, and experimental models.
What was found
ALA consistently improved short-term neuropathy symptoms across multiple randomized trials. In the long-term NATHAN 1 trial, ALA showed a marginal, borderline significant effect on the primary composite endpoint (NIS-LL, p = 0.05) with no significant improvement in nerve conduction studies. Benfotiamine demonstrated biochemical plausibility (transketolase activation) but clinical evidence was restricted to short-duration, symptom-based studies with no large-scale long-term trials; routine use cannot be recommended without documented thiamine deficiency.
Why it matters
This review distinguishes symptomatic relief from disease modification in DPN, clarifying that neither ALA nor benfotiamine currently has sufficient evidence for nerve regeneration or structural stabilization.
Limits
The paper is a qualitative narrative review rather than a systematic review or meta-analysis; study counts and search dates were not reported in the abstract. Clinical evidence for both agents is limited by short intervention durations, reliance on subjective symptom scores, and lack of structural or objective biomarker endpoints.
Cited by
- partial Peripheral neuropathy can usually be greatly improved with benfotiamine and alpha-lipoic acid.